Other News Releases in Health Care & Hospitals
Congressman Fattah: Thanks to Specter, Casey for a Major Step Along History's Path
Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure
Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill
Other News Releases in Trade Show News
River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries
ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries
U.S.-China Business Summit to Host World's Largest Symposium for Americans, Chinese
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Trade Show News
Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
PT. RICHMOND, Calif., Nov. 14 /PRNewswire/ -- Transcept
Pharmaceuticals, Inc. today announced that Thomas P. Soloway, Senior Vice
President and Chief Financial Officer, will present at the 19th Annual
Piper Jaffray Health Care Conference at the Pierre Hotel in New York City
on Tuesday, November 27, 2007 at 10:30 AM Eastern Time.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company
deriving significant new patient benefits from proven CNS drugs. Transcept
development projects leverage new understanding of CNS conditions to
provide additional uses and enhanced clinical benefits for existing active
agents. The lead Transcept product, Intermezzo(R) (zolpidem tartrate
lozenge), is a low dose sublingual formulation of zolpidem that is
currently in late phase 3 clinical trials for the treatment of insomnia in
patients who awaken in the middle of the night and have difficulty
returning to sleep. Another product being developed by Transcept is
TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for
the treatment of dopamine associated psychiatric disorders. TO-2060 is
currently the subject of an initial proof of concept trial in the treatment
of alcohol use disorder. For more information, please visit the company's
website at: http://www.transcept.com.
Contacts:
Transcept Pharmaceuticals, Inc. The Ruth Group
Michael Gill, Investors / Media
Director of Communications Stephanie Carrington / Jason Rando
(510) 215-3575 (646) 536-7017 / 7025
mgill@transcept.com scarrington@theruthgroup.com
jrando@theruthgroup.com
SOURCE Transcept Pharmaceuticals, Inc.